Share on LinkedInShare on LinkedIn

ARTICLE · 16 FEBRUARY 2016

When A "Promise"‎ Negates The Utility Of A Patent

Marks & Clerk
Marks & Clerk
Contributor
Marks & Clerk

Marks & Clerk

Marks & Clerk LLP was founded in 1887 by George Croydon Marks, who was joined in partnership by...

View firm profile
Explore more from Marks & Clerk

In Canada, valid patents must have "utility" – a similar concept to "industrial application", as required in European patent applications.

CanadaIntellectual Property

In Canada, valid patents must have "utility" – a similar concept to "industrial application", as required in European patent applications. However, in some cases, utility cannot be fully verified by tests at the time of filing the patent application. In these instances, utility must be soundly predicted.

In Sanofi-Aventis v Apotex (2013 FCA 186), the Federal Court of Appeal (FCA) confirmed and updated the "promise of a patent" doctrine by qualifying that such a promise must be explicit within the patent application (as outlined in our previous article).

This doctrine has been subsequently developed by the FCA, such as in the 2015 decision relating to AstraZeneca's Canadian Patent 2,139,653 for esomeprazole (NEXIUM) (AstraZeneca Canada v Apotex [2015 FCA 158]), in which the FCA found the patent to be invalid for lack of utility because it failed to meet at least one promise identified by the court in the application's description. These subsequent decisions shed

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from